Pharma
Lucent Diagnostics, a diagnostics brand owned by Quanterix, has partnered with Tempus to integrate blood-based Alzheimer’s biomarker testing into clinical workflows used by neurologists. The companies said the collaboration will allow physicians using Tempus Next to identify patients who may benefit from biomarker testing and order LucentAD Complete directly through existing electronic health record (EHR) integrations.
LucentAD Complete is a blood-based Alzheimer’s assessment test that measures biomarkers associated with amyloid pathology, neurodegeneration, and neuroinflammation. According to Lucent Diagnostics, the test combines measurements including p-Tau217, Aβ42/40, GFAP, and NfL into a multi-analyte algorithmic assessment.
Tempus said its Tempus Next platform uses AI-enabled care pathway intelligence to identify care gaps and surface guideline-based clinical insights at the point of care. The company has been expanding the platform across multiple disease areas as part of a broader push into AI-driven diagnostics and clinical workflow infrastructure.
